-+ 0.00%
-+ 0.00%
-+ 0.00%

First Hawaiian (FHB) Stock Price Questions How Long Q3 Margin Strength Lasts

Simply Wall St·10/24/2026 00:41:42
语音播报

First Hawaiian stock slipped about 3% to US$25.34 after the Q3 2026 earnings release, giving the impression of a routine regional bank setback. The headline tells a different story. Net interest income landed at US$174.1 million and the net interest margin, the core profitability gauge for lenders, came in at 3.30%. That is where the real tension lies for long term holders. The market is focused on the red print on the screen today, while the multi year case now turns on how durable this margin profile and the bank’s capital position prove to be.

Love First Hawaiian’s current margin profile but uneasy about how long it can hold up as loan growth and funding costs pull in opposite directions? Compare this setup with banks and financials on our list of solid balance sheet and fundamentals stocks (25 results)

Q3 2026 Earnings Summary

  • Total Revenue (Q3 2026 vs. Q3 2025): US$209.9 million vs. US$221.9 million (down about 5%)
  • Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$63.7 million vs. US$73.8 million (down about 14%)
  • Basic EPS (Q3 2026 vs. Q3 2025): US$0.52 vs. US$0.59 (down about 12%)
  • Net Interest Margin (NIM, Q3 2026 vs. Q3 2025): 3.30% vs. 3.19% (up around 11 basis points)

Earnings for First Hawaiian are one snapshot, but investors who care about valuation usually pay more attention to the cash that actually comes through the business. Accounting profit can look flat while free cash flow tells a different story.

When you line up First Hawaiian's recent cash generation against its current share price, the stock could be a dramatic 45% undervalued.

NasdaqGS:FHB Trailing 12-Month Earnings & Revenue History as at Oct 2026
NasdaqGS:FHB Trailing 12-Month Earnings & Revenue History as at Oct 2026

First Hawaiian’s TriCo Growth Story On Trial

The bullish idea is that TriCo turns First Hawaiian into a bigger, stronger earnings engine, not just a larger balance sheet.

"The all stock acquisition of TriCo Bancshares, which is expected to close near the end of 2026, is planned to create a combined First Hawaiian platform with about US$34b of assets, US$29b of deposits and 117 branches."

Q3 points in that direction. Deposits edged up about US$50m with noninterest bearing balances at 32%, and NIM reached 3.30% with September at 3.33%. Operating expenses, stripping out merger and tax items, ran below expectations. The TriCo platform is not live yet, but underlying efficiency and funding metrics are tracking in line with a larger, low cost model.

Testing Fears Around TriCo Integration And Funding

Bears worry the TriCo deal and funding pressures could erode the very economics the merger is meant to improve.

"Execution risk around the TriCo Bancshares acquisition, including integration of systems, retention of key TriCo leaders and delivery of the targeted 25% cost savings with no branch closures, could undermine the expected 6% earnings per share accretion and high teens internal rate of return."

Integration work is already costing cash, with US$6.7m of merger expenses in Q3 and another US$25m flagged for Q4, while the share price fell about 3% on the day of the release. At the same time, the feared funding strain is not visible yet. Total deposits ticked higher, the noninterest bearing mix held at 32%, and deposit costs actually eased by about 3 bps.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Hunt For Quiet Mispricings

First Hawaiian just reminded you that a busy earnings print and a small price move can tell very different stories. The real opportunity is spotting stocks that could be undervalued before expectations and prices catch up.

  • Company 1 - 28% below our estimate - supplies liquid cooling equipment as dense GPU racks strain legacy air-based systems.
  • Company 2 - 42% below our estimate - sells LED display and control platforms as cities adopt connected digital signage infrastructure.
  • Company 3 - 25% below our estimate - develops injectable therapies for weight management and diabetes used in front line care.

Three companies from the same screener. Open all 27 potentially undervalued companies →